http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
흑색종 환자에서 면역관문 억제제 (Immune Checkpoint Inhibitor)의 효과에 대해 피부과적 부작용 및 영향을 미치는 인자들에 관한 분석: 단일 기관 후향적 연구
윤도경 ( Dokyoung Yoon ),오세진 ( Se Jin Oh ),김현제 ( Hyun Je Kim ),박지혜 ( Ji-hye Park ),이종희 ( Jong Hee Lee ),이동윤 ( Dong-youn Lee ),이주흥 ( Joo-heung Lee ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.4
Background: Programmed death 1 inhibitors enhance pre-existing immune responses by directly blocking anti-programmed cell death receptor-1. They have been widely used these days, but little is known about the dermatologic side effects and the factors affecting the response to therapy. Objective: To determine the association between dermatologic side effects and oncologic response to programmed death 1 inhibitors and to investigate the factors affecting the response to programmed death 1 inhibitors. Methods: We retrospectively reviewed the records of patients with melanoma who were referred to the dermatology department for their newly arising skin lesions after treatment with pembrolizumab and nivolumab from January 1, 2015, to April 30, 2019. The oncologic outcomes of the patients were determined by medical records from the hemato-oncology department. Sex, stage, dermatologic side effects, and age at the time of initial diagnosis were analyzed as the factors affecting oncologic outcomes. Progression-free survival was analyzed between the patients with and those without dermatologic side effects. Results: Of the 177 patients screened for the study, 14 were referred to the dermatology department for cutaneous side effects. There was no difference between the dermatologic side effect group and the non-dermatologic side effect group in terms of oncologic outcome and progression-free survival. Sex and stage significantly increased the risk of disease progression with pembrolizumab treatment. Conclusion: Although it has been reported that there could be a strong association between dermatologic side effects and oncologic outcomes, we were not able to reach the same conclusion among melanoma patients. (Korean J Dermatol 2021;59(4):251∼258)